Chronic Graft vs Host Disease Clinical Trial
Official title:
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in Patients Who do Not Obtain Complete Remission With Ruxolitinib
A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib
The study design is based on a phase I trial in Spanish. A number of 16 patients will be included to assess the safety and maximum tolerated dose-level of donor regulatory enriched T cell (Treg) in steroid-refractory chronic graft versus host disease (cGVHD) patients who did not obtain complete remission under treatment with ruxolitinib. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01221766 -
Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease
|
N/A | |
Active, not recruiting |
NCT02067832 -
Predictive Biomarkers For Pediatric Chronic Graft-Versus-Host Disease
|
||
Active, not recruiting |
NCT02759731 -
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
Recruiting |
NCT05095649 -
Donor Regulatory T-cells for cGVHD in Patients Who do Not Obtain Complete Remission With Ruxolitinib
|
Phase 2 | |
Terminated |
NCT04852692 -
A Study to Investigate the Comparative Effectiveness of Ibrutinib in Steroid Dependent/Refractory cGVHD Participants
|
||
Recruiting |
NCT02669251 -
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 |